Mechanistic insights from sequential combination therapy with a sodium glucose co ‐transporter‐2 inhibitor and a dipeptidyl peptidase‐4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin

Diabetes, Obesity and Metabolism, EarlyView.

Source: Diabetes, Obesity and Metabolism - September 26, 2018 Category: Endocrinology Authors: Sumie Okahata, Kentaro Sakamoto, Takako Mitsumatsu, Yuko Kondo, Shoji Tanaka, Teruo Shiba Source Type: research